Adam Rosenberg, J.D.

Adam was the founding chief executive officer of Sionna and is also a venture partner at RA Capital Management. He has over 20 years of experience leading biopharmaceutical companies across various stages. Previously, he was the chief executive officer of Rodin Therapeutics until its acquisition by Alkermes in 2019. Adam was also co-founder and CEO of Teleos Therapeutics and Link Medicine Corporation. He currently serves on multiple private company boards. Adam received his J.D. from the University of Virginia School of Law and holds a B.A. from Whittier College.